Natalie Cureton - Concepedia

Author

Natalie Cureton

Also Known As

Natalie Cureton

Publications

236

Citations

H-Index

Concepts

All Affiliations

Natalie Cureton is an author at AstraZeneca (United Kingdom) specializing in molecular pharmacology, drug discovery, and tumor biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	13
2	Natural Sciences	1	1	13
3	Biomolecular Engineering	1	1	13
4	Chemical Biology	1	1	13
5	Endocrinology	1	1	13

Natalie Cureton

Publications

229

Citations

H-Index

Page 1

	Year	Citations
Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy Natalie Cureton, I. P. Korotkova, Bernadette Baker, Theranostics	2017	97
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance Mandy Lawson, Natalie Cureton, Susana R�os, Cancer Research	2023	54
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors Shanade Dunn, Cath Eberlein, Jason Yu, Oncogene	2022	30
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC Thomas G. Hayhow, Beth Williamson, Mandy Lawson, Communications Biology	2024	19
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists James S. Scott, Darren Stead, Bernard Barlaam, Journal of Medicinal Chemistry	2023	16
Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD) James S. Scott, Steve Stokes, Willem Nissink, Cancer Research Breast OncologyEstrogen ReceptorAbstract 5674Chemical BiologyMammary Gland Development	2020	13

Page 1